The extensive use of daptomycin (DAP) for treatment of methicillin-resistant Staphylococcus
aureus (MRSA) infections in the last decade has led to the emergence of DAP non …

Daptomycin is increasingly used in combination with other antibiotics to enhance
antimicrobial efficacy and/or to mitigate the emergence of daptomycin nonsusceptibility …

Objectives Daptomycin non-susceptibility in Staphylococcus aureus can emerge via the
accumulation of single or multiple mutations, each resulting in a slight increase in the …

Daptomycin resistance (DAPR) in Staphylococcus aureus is associated with mutations in
genes that are also implicated in staphylococcal pathogenesis. Using a laboratory-derived …

Daptomycin (DAP) represents an interesting alternative to treat methicillin-resistant
Staphylococcus aureus (MRSA) infections. Different mechanisms of DAP resistance have …

The objective of this study was to investigate the underlying mechanism explaining
reversion of clinical DAP non-susceptible (NS) MRSA isolates to DAP-susceptible (S) by …

Daptomycin is a lipopeptide antibiotic with potent activity against gram-positive bacteria.
Complete-genome comparisons of laboratory-derived Staphylococcus aureus with …

Daptomycin (DAP) has potent activity in vitro and in vivo against both methicillin-susceptible
Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains. DAP …

The mechanisms leading to reduced susceptibility to daptomycin (DAP) are multifactorial
and have not been fully elucidated. We analysed, by sequencing and expression studies …

Development of in vivo daptomycin resistance (DAP-R) among Staphylococcus aureus
clinical isolates, in association with clinical treatment failures, has become a major …